475 related articles for article (PubMed ID: 15119978)
1. Matrix metalloproteinases: contribution to pathogenesis, diagnosis, surveillance and treatment of abdominal aortic aneurysms.
Kadoglou NP; Liapis CD
Curr Med Res Opin; 2004 Apr; 20(4):419-32. PubMed ID: 15119978
[TBL] [Abstract][Full Text] [Related]
2. Relationships between matrix metalloproteinases and tissue inhibitor of metalloproteinases in the wall of abdominal aortic aneurysms.
Nishimura K; Ikebuchi M; Kanaoka Y; Ohgi S; Ueta E; Nanba E; Ito H
Int Angiol; 2003 Sep; 22(3):229-38. PubMed ID: 14612849
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinases and abdominal aortic aneurysms: a potential therapeutic target.
Sinha S; Frishman WH
J Clin Pharmacol; 1998 Dec; 38(12):1077-88. PubMed ID: 11301559
[TBL] [Abstract][Full Text] [Related]
4. Expression of matrix metalloproteinases, their tissue inhibitors, and osteopontin in the wall of thoracic and abdominal aortas with dilatative pathology.
Lesauskaite V; Epistolato MC; Castagnini M; Urbonavicius S; Tanganelli P
Hum Pathol; 2006 Aug; 37(8):1076-84. PubMed ID: 16867871
[TBL] [Abstract][Full Text] [Related]
5. Expression of matrix metalloproteinases and TIMPs in human abdominal aortic aneurysms.
Elmore JR; Keister BF; Franklin DP; Youkey JR; Carey DJ
Ann Vasc Surg; 1998 May; 12(3):221-8. PubMed ID: 9588507
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinase-8 and -9 are increased at the site of abdominal aortic aneurysm rupture.
Wilson WR; Anderton M; Schwalbe EC; Jones JL; Furness PN; Bell PR; Thompson MM
Circulation; 2006 Jan; 113(3):438-45. PubMed ID: 16432074
[TBL] [Abstract][Full Text] [Related]
7. [Matrix metalloproteinases and atherosclerosis. Therapeutic aspects].
Beaudeux JL; Giral P; Bruckert E; Foglietti MJ; Chapman MJ
Ann Biol Clin (Paris); 2003; 61(2):147-58. PubMed ID: 12702469
[TBL] [Abstract][Full Text] [Related]
8. Abdominal aortic aneurysm and abdominal wall hernia as manifestations of a connective tissue disorder.
Antoniou GA; Georgiadis GS; Antoniou SA; Granderath FA; Giannoukas AD; Lazarides MK
J Vasc Surg; 2011 Oct; 54(4):1175-81. PubMed ID: 21820838
[TBL] [Abstract][Full Text] [Related]
9. Inflammatory infiltrates and neovessels are relevant sources of MMPs in abdominal aortic aneurysm wall.
Reeps C; Pelisek J; Seidl S; Schuster T; Zimmermann A; Kuehnl A; Eckstein HH
Pathobiology; 2009; 76(5):243-52. PubMed ID: 19816084
[TBL] [Abstract][Full Text] [Related]
10. Difference in matrix-degrading protease expression and activity between thrombus-free and thrombus-covered wall of abdominal aortic aneurysm.
Kazi M; Zhu C; Roy J; Paulsson-Berne G; Hamsten A; Swedenborg J; Hedin U; Eriksson P
Arterioscler Thromb Vasc Biol; 2005 Jul; 25(7):1341-6. PubMed ID: 15845912
[TBL] [Abstract][Full Text] [Related]
11. [Extracellular matrix -- from basic research to clinical significance. An overview with special consideration of matrix metalloproteinases].
Hamacher S; Matern S; Roeb E
Dtsch Med Wochenschr; 2004 Sep; 129(38):1976-80. PubMed ID: 15375740
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of ets, an essential transcription factor for angiogenesis, to prevent the development of abdominal aortic aneurysm in a rat model.
Miwa K; Nakashima H; Aoki M; Miyake T; Kawasaki T; Iwai M; Oishi M; Kataoka K; Ohgi S; Ogihara T; Kaneda Y; Morishita R
Gene Ther; 2005 Jul; 12(14):1109-18. PubMed ID: 15800662
[TBL] [Abstract][Full Text] [Related]
13. Abdominal aortic aneurysm as a complex multifactorial disease: interactions of polymorphisms of inflammatory genes, features of autoimmunity, and current status of MMPs.
Pearce WH; Shively VP
Ann N Y Acad Sci; 2006 Nov; 1085():117-32. PubMed ID: 17182928
[TBL] [Abstract][Full Text] [Related]
14. Matrix metalloproteinases and their inhibitors in non-neoplastic otorhinolaryngological disease.
De S; Fenton JE; Jones AS
J Laryngol Otol; 2005 Jun; 119(6):436-42. PubMed ID: 15992468
[TBL] [Abstract][Full Text] [Related]
15. Doxycycline therapy for abdominal aneurysm: Improved proteolytic balance through reduced neutrophil content.
Abdul-Hussien H; Hanemaaijer R; Verheijen JH; van Bockel JH; Geelkerken RH; Lindeman JH
J Vasc Surg; 2009 Mar; 49(3):741-9. PubMed ID: 19268776
[TBL] [Abstract][Full Text] [Related]
16. Elevated plasma MMP1 and MMP9 are associated with abdominal aortic aneurysm rupture.
Wilson WR; Anderton M; Choke EC; Dawson J; Loftus IM; Thompson MM
Eur J Vasc Endovasc Surg; 2008 May; 35(5):580-4. PubMed ID: 18226564
[TBL] [Abstract][Full Text] [Related]
17. Matrix metalloproteinase 8 (neutrophil collagenase) in the pathogenesis of abdominal aortic aneurysm.
Wilson WR; Schwalbe EC; Jones JL; Bell PR; Thompson MM
Br J Surg; 2005 Jul; 92(7):828-33. PubMed ID: 15918165
[TBL] [Abstract][Full Text] [Related]
18. HMG-CoA reductase inhibitors (statins) decrease MMP-3 and MMP-9 concentrations in abdominal aortic aneurysms.
Wilson WR; Evans J; Bell PR; Thompson MM
Eur J Vasc Endovasc Surg; 2005 Sep; 30(3):259-62. PubMed ID: 16009575
[TBL] [Abstract][Full Text] [Related]
19. A randomized placebo controlled trial of the effect of preoperative statin use on matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in areas of low and peak wall stress in patients undergoing elective open repair of abdominal aortic aneurysm.
Rahman MN; Khan JA; Mazari FA; Mockford K; McCollum PT; Chetter IC
Ann Vasc Surg; 2011 Jan; 25(1):32-8. PubMed ID: 20889295
[TBL] [Abstract][Full Text] [Related]
20. Extracellular matrix remodelling in human aortic valve disease: the role of matrix metalloproteinases and their tissue inhibitors.
Fondard O; Detaint D; Iung B; Choqueux C; Adle-Biassette H; Jarraya M; Hvass U; Couetil JP; Henin D; Michel JB; Vahanian A; Jacob MP
Eur Heart J; 2005 Jul; 26(13):1333-41. PubMed ID: 15827062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
